Intracerebral Hemorrhage – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Intracerebral Hemorrhage – Drugs In Development, 2024 report and make more profitable business decisions.
Intracerebral hemorrhage (ICH), a devastating stroke subtype, involves the formation of a hematoma within the brain parenchyma, with or without extension into the ventricles. Accounting for 10-15% of all strokes, non-traumatic ICH is linked to high morbidity and mortality. Risk factors encompass chronic hypertension, amyloid angiopathy, anticoagulation, and vascular malformations. The resulting brain injury is categorized as primary, signifying initial damage by the blood clot, or secondary, indicating complications from intracranial blood. Management options for ICH span from medical therapy to surgical evacuation of the hematoma, prompting ongoing studies for less invasive interventions to enhance prognosis.
The Intracerebral Hemorrhage drugs in development market research report provide comprehensive information on the therapeutics under development for Intracerebral Hemorrhage, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Intracerebral Hemorrhage and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Intracerebral Hemorrhage | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 18 molecules, with 18 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Intracerebral Hemorrhage therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Intracerebral Hemorrhage pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Intracerebral Hemorrhage treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AegisCN LLCAmylon Therapeutics BV
AptaTargets SL
Bioxodes SA
Cenyx Biotech Inc
EmstoPA Ltd
Neurodawn Pharmaceutical Co Ltd
Neuronasal LLC
NeuroTrauma Sciences LLC
Op2Lysis SAS
PharmaReview Corp
RxMP Therapeutics LLC
Simcere Pharmaceutical Group Ltd
Sinobioway Biomedical Co Ltd
Swedish Orphan Biovitrum AB
Tiziana Life Sciences Plc
Worphmed Srl
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Intracerebral Hemorrhage reports